Regulation of lipid metabolism by p53 - fighting two villains with one sword

Trends in Endocrinology and Metabolism

Volumn 23, Issue 11, 2012, Pages 567-575

  Goldstein, Ido ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ADENYLATE KINASE; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CARBOXYLESTERASE; CELL NUCLEUS RECEPTOR; CELL PROTEIN; CERAMIDE; GUANIDINOACETATE METHYLTRANSFERASE; LIPIN 1; MAMMALIAN TARGET OF RAPAMYCIN; OXIDOREDUCTASE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEIN DHRS3; PROTEIN NR0B2; PROTEIN P53; SPHINGOLIPID; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CANCER INHIBITION; CAUSE OF DEATH; CELL FATE; CELL TRANSFORMATION; GENE CONTROL; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIPOPROTEINS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867142011     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.06.007     Document Type: Review

References (79)

1. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
2. Bensaad K., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
3. Hu W., et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7455-7460.
4. Kawauchi K., et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
5. Kondoh H., et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
6. Matoba S., et al. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
7. Schwartzenberg-Bar-Yoseph F., et al. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64:2627-2633.
8. Stambolsky P., et al. Regulation of AIF expression by p53. Cell Death Differ. 2006, 13:2140-2149.
9. Suzuki S., et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7461-7466.
10. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
11. DeBerardinis R.J., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
12. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
13. Maddocks O.D., Vousden K.H. Metabolic regulation by p53. J. Mol. Med. (Berl.) 2011, 89:237-245.
14. Lehninger Principles of Biochemistry 2004, W.H. Freeman and Company. L.N. David, M. Cox (Eds.).
15. Ide T., et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol. Cell 2009, 36:379-392.
16. Assaily W., et al. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol. Cell 2011, 44:491-501.
17. Finck B.N., et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006, 4:199-210.
18. Sen N., et al. PGC-1alpha, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 2011, 44:621-634.
19. Liu C., Lin J.D. PGC-1 coactivators in the control of energy metabolism. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:248-257.
20. Goldstein I., et al. p53, a novel regulator of lipid metabolism pathways. J. Hepatol. 2012, 56:656-662.
21. Zaugg K., et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25:1041-1051.
22. Jogl G., et al. Structure and function of carnitine acyltransferases. Ann. N. Y. Acad. Sci. 2004, 1033:17-29.
23. Hardwick J.P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 2008, 75:2263-2275.
24. Jiang P., et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
25. Yahagi N., et al. p53 Activation in adipocytes of obese mice. J. Biol. Chem. 2003, 278:25395-25400.
26. Bazuine M., et al. Guardian of corpulence: a hypothesis on p53 signaling in the fat cell. Clin. Lipidol. 2009, 4:231-243.
27. Molchadsky A., et al. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010, 31:1501-1508.
28. Medes G., et al. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953, 13:27-29.
29. Swinnen J.V., et al. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
30. Li T., et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
31. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
32. Goldstein I., et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011, 18:2-11.
33. Freed-Pastor W.A., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
34. Clendening J.W., et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15051-15056.
35. Koyuturk M., et al. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 2007, 250:220-228.
36. Pullinger C.R., Kane J.P. Lipid and lipoprotein metabolism. Encyclopedia of Molecular Cell biology and Molecular Medicine 2005, 10.1002/3527600906.mcb.200400101. D.A. Myers (Ed.).
37. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 2012, 13:213-224.
38. Ashur-Fabian O., et al. apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle 2010, 9:3761-3770.
39. Yazdanyar A., et al. Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport. Curr. Atheroscler. Rep. 2011, 13:242-248.
40. Camarota L.M., et al. Carboxyl ester lipase cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3. J. Biol. Chem. 2004, 279:27599-27606.
41. Li F., et al. Bile salt stimulated cholesterol esterase increases uptake of high density lipoprotein-associated cholesteryl esters by HepG2 cells. Biochemistry 1996, 35:6657-6663.
42. Hu Y.W., et al. Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. Biochim. Biophys. Acta 2010, 1801:100-105.
43. Kim D.H., Lee J.W. Tumor suppressor p53 regulates bile acid homeostasis via small heterodimer partner. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12266-12270.
44. Norlin M., Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 2007, 7:199-218.
45. Bist A., et al. p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. Biochemistry 2000, 39:1966-1972.
46. Smyth I., et al. A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. PLoS Genet. 2008, 4:e1000192.
47. Ye D., et al. Macrophage ABCA5 deficiency influences cellular cholesterol efflux and increases susceptibility to atherosclerosis in female LDLr knockout mice. Biochem. Biophys. Res. Commun. 2010, 395:387-394.
48. Libby P., et al. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
49. Guevara N.V., et al. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 1999, 5:335-339.
50. Merched A.J., et al. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1608-1614.
51. Boesten L.S., et al. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis 2009, 207:399-404.
52. van Vlijmen B.J., et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 2001, 88:780-786.
53. Mercer J., et al. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res. 2005, 96:667-674.
54. Oram J.F., et al. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J. Biol. Chem. 2003, 278:52379-52385.
55. Schgoer W., et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008, 196:219-226.
56. Yatsuya H., et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ. J. 2004, 68:11-16.
57. Christoffersen C., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J. Biol. Chem. 2008, 283:1839-1847.
58. Wolfrum C., et al. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat. Med. 2005, 11:418-422.
59. Belyi V.A., et al. The origins and evolution of the p53 family of genes. Cold Spring Harb. Perspect. Biol. 2010, 2:a001198.
60. Cohen J.C., et al. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
61. Yahagi N., et al. p53 involvement in the pathogenesis of fatty liver disease. J. Biol. Chem. 2004, 279:20571-20575.
62. Deisenroth C., et al. p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation. J. Biol. Chem. 2011, 286:28343-28356.
63. Kirschner R.D., et al. The retinal dehydrogenase/reductase retSDR1/DHRS3 gene is activated by p53 and p63 but not by mutants derived from tumors or EEC/ADULT malformation syndromes. Cell Cycle 2010, 9:2177-2188.
64. Shangary S., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 2009, 49:223-241.
65. Ogretmen B., Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 2004, 4:604-616.
66. Heffernan-Stroud L.A., Obeid L.M. p53 and regulation of bioactive sphingolipids. Adv. Enzyme Regul. 2011, 51:219-228.
67. Panjarian S., et al. De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation. Prostaglandins Other Lipid Mediat. 2008, 86:41-48.
68. Cuvillier O., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
69. Olivera A., et al. Sphingosine kinase type 1 induces G12/13-mediated stress fiber formation, yet promotes growth and survival independent of G protein-coupled receptors. J. Biol. Chem. 2003, 278:46452-46460.
70. Van Brocklyn J.R., et al. Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett. 2003, 199:53-60.
71. Xia P., et al. An oncogenic role of sphingosine kinase. Curr. Biol. 2000, 10:1527-1530.
72. Taha T.A., et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J. Biol. Chem. 2004, 279:20546-20554.
73. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25:1895-1908.
74. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
75. Porstmann T., et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8:224-236.
76. Feng Z., Levine A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010, 20:427-434.
77. Imamura K., et al. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 287:562-567.
78. Jones R.G., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
79. Buzzai M., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007, 67:6745-6752.